Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Table 2

Mean (standard deviation) number of anti-VEGF therapy and PDT in the regimen of anti-VEGF monotherapy and the regimen of combination therapy for various subtypes of polypoidal choroidal vasculopathy during the 6-year period.

	Subtype 1			Subtype 2
	Anti-VEGF monotherapy	Combination therapy		Anti-VEGF monotherapy	Combination therapy
		Anti-VEGF therapy	PDT		Anti-VEGF therapy	PDT
Year 1	2.73 (1.10)	4.62 (3.10)	1.00 (0)	2.62 (2.57)	2.40 (1.84)	1.00 (0)
Year 2	1.09 (1.14)	1.77 (1.88)	0 (0)	0.62 (1.19)	1.10 (1.10)	0.20 (0.42)
Year 3	1.82 (1.94)	1.54 (1.76)	0.15 (0.38)	0.69 (1.55)	0.40 (0.70)	0.10 (0.32)
Year 4	1.27 (2.00)	1.46 (1.56)	0 (0)	0.23 (0.60)	1.60 (2.91)	0.20 (0.42)
Year 5	0.91 (1.22)	1.00 (1.08)	0 (0)	0 (0)	0.90 (0.99)	0 (0)
Year 6	0.91 (1.38)	0.62 (0.51)	0 (0)	0.15 (0.38)	0.70 (1.06)	0 (0)
Total	8.73 (6.17)	11.00 (4.24)	1.15 (0.38)	4.31 (3.71)	7.10 (5.97)	1.50 (0.71)

PDT, photodynamic therapy; VEGF, vascular endothelial growth factor.